AFMD stock is under heavy selling pressure this morning after Affimed NV (NASDAQ:AFMD) announces the termination of Phase 1 clinical program of AFM11, a CD19/CD3-targeting bispecific T cell engager.
AFMD stock TumblesGermany based biopharmaceutical company Affirmed NV has been one of the better-known outfits in the cancer drug industry due to the nature of the drugs it produces. The company is engaged in producing cancer drugs that allow patients to regain the strength that is necessary to battle cancer. However, the company made an announcement that would come as a bit of a disappointment for ...
Read The Full Article On MicroSmallCap.com
Get early insight on hidden secret gems on MicroSmallCap. Follow Crypto, Mining, Cannabis and Energy stocks and get free research reports here.
All content provided by MicroSmallCap is subject to our Terms Of Use and Disclaimer.